These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22075444)

  • 1. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network.
    DeFoe SG; Beriwal S; Jones H; Rakfal S; Heron DE; Kabolizadeh P; Smith RP; Lalonde R
    Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):424-31. PubMed ID: 22075444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
    Salama JK; Mell LK; Schomas DA; Miller RC; Devisetty K; Jani AB; Mundt AJ; Roeske JC; Liauw SL; Chmura SJ
    J Clin Oncol; 2007 Oct; 25(29):4581-6. PubMed ID: 17925552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
    Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
    Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
    Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
    Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
    Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
    Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
    Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
    Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
    Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
    Wright JL; Patil SM; Temple LK; Minsky BD; Saltz LB; Goodman KA
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1064-72. PubMed ID: 20350793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
    Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
    Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
    Ferrigno R; Nakamura RA; Dos Santos Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV; Filho WJ; Lopes A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1136-42. PubMed ID: 15752894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
    Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
    Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
    DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
    Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
    Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
    Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
    Fraunholz I; Weiss C; Eberlein K; Haberl A; Rödel C
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1425-32. PubMed ID: 19744801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
    Seo Y; Kinsella MT; Reynolds HL; Chipman G; Remick SC; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):143-9. PubMed ID: 19203845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
    Hatfield P; Cooper R; Sebag-Montefiore D
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):419-24. PubMed ID: 17919842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.